Amplia Therapeutics Limited
Amplia Therapeutics Limited
Your view on ATX.AX
Overview
What the company does, where it operates, and who runs it.
About Amplia Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chris Burns
- Headquarters
- 90 William Street, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chris Burns
- Headquarters
- 90 William Street, Melbourne, VIC, AU
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.
The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Amplia Therapeutics Limited. Starting points for Amplia Therapeutics Limited: EPS -AUD 0.02, beta -0.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Amplia Therapeutics Limited. Amplia Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Amplia Therapeutics Limited. Trailing twelve-month EPS for Amplia Therapeutics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|
| Avg. estimate | −AUD 0.02 | −AUD 0.01 |
| Low estimate | −AUD 0.02 | −AUD 0.01 |
| High estimate | −AUD 0.02 | −AUD 0.01 |
| No. of analysts | 1 | 1 |
| Year-ago EPS | −AUD 0.02 | — |
| Growth | −40.2% | — |
Revenue Estimate
| Revenue | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|
| Avg. estimate | AUD 0.00 | AUD 9.50M |
| Low estimate | AUD 0.00 | AUD 9.50M |
| High estimate | AUD 0.00 | AUD 9.50M |
| No. of analysts | 0 | 1 |
| Year-ago revenue | AUD 0.00 | — |
| Growth | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Amplia Therapeutics Limited. Amplia Therapeutics Limited has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| BMT.AXBeamtree Holdings Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| CYC.AXCyclopharm Limited | Healthcare | Medical - Devices | — | ||
| CYP.AXCynata Therapeutics Limited | Healthcare | Biotechnology | — | ||
| GSS.AXGenetic Signatures Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| IPD.AXImpediMed Limited | Healthcare | Medical - Devices | — | ||
| M7T.AXMach7 Technologies Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| MX1.AXMicro-X Limited | Healthcare | Medical - Devices | — | ||
| PIQ.AXProteomics International Laboratories Ltd. | Healthcare | Medical - Care Facilities | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $65.1M | ||
| POLBFPoolbeg Pharma PLC | Healthcare | OTC | $46.6M | ||
| PPBTPurple Biotech Ltd. | Healthcare | NASDAQ | $236,124 | ||
| PPCBPropanc Biopharma Inc. Common Stock | Healthcare | NASDAQ | $1.8M | ||
| PPTDFPeptiDream Inc. | Healthcare | OTC | $1.1B | ||
| PRAXPraxis Precision Medicines, Inc. | Healthcare | NASDAQ | $8.5B | ||
| PREDQPredictive Discovery Limited | Healthcare | OTC | $2,996 | ||
| PREV.CNPreveCeutical Medical Inc. | Healthcare | CNQ | $11.7M | ||
| PRLDPrelude Therapeutics Incorporated | Healthcare | NASDAQ | $191.0M | ||
| PRMEPrime Medicine, Inc. | Healthcare | NASDAQ | $694.9M | ||
| PRNAFAlterity Therapeutics Limited | Healthcare | OTC | $109.8M | ||
| PROKProKidney Corp. | Healthcare | NASDAQ | $349.7M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Amplia Therapeutics Limited. Coverage tracks Amplia Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Amplia Therapeutics Limited.